

Craig J Thomas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2101320/publications.pdf>

Version: 2024-02-01

46
papers

7,061
citations

185998

28
h-index

223531

46
g-index

48
all docs

48
docs citations

48
times ranked

10272
citing authors

#	ARTICLE	IF	CITATIONS
1	Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. <i>Nature</i> , 2010, 463, 88-92.	13.7	1,402
2	NMDAR inhibition-independent antidepressant actions of ketamine metabolites. <i>Nature</i> , 2016, 533, 481-486.	13.7	1,246
3	Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. <i>Pharmacological Reviews</i> , 2018, 70, 621-660.	7.1	723
4	Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma. <i>Cancer Cell</i> , 2012, 21, 723-737.	7.7	460
5	Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. <i>Cancer Cell</i> , 2017, 31, 833-843.e5.	7.7	383
6	High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 2349-2354.	3.3	355
7	Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. <i>Nature</i> , 2017, 549, 533-537.	13.7	350
8	A multiprotein supercomplex controlling oncogenic signalling in lymphoma. <i>Nature</i> , 2018, 560, 387-391.	13.7	276
9	Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome. <i>Cancer Cell</i> , 2013, 24, 90-104.	7.7	168
10	Blockade of oncogenic $\text{I}\kappa\text{B}$ kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 11365-11370.	3.3	166
11	Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	129
12	Antidepressant-relevant concentrations of the ketamine metabolite (2 <i>R</i> ,6 <i>R</i>)-hydroxynorketamine exerts mGlu ₂ receptor-dependent antidepressant actions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 5160-5169.	3.3	120
13	A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Cancer Cell</i> , 2016, 30, 764-778.	7.7	116
14	(2 <i>R</i> ,6 <i>R</i>)-hydroxynorketamine exerts mGlu ₂ receptor-dependent antidepressant actions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 6441-6450.	3.3	112
15	Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. <i>Cancer Cell</i> , 2021, 39, 566-579.e7.	7.7	107
16	High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations. <i>Scientific Reports</i> , 2015, 5, 13891.	1.6	92
17	RUC-4. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 2321-2329.	1.1	71
18	Synthesis and N-Methyl-aspartate (NMDA) Receptor Activity of Ketamine Metabolites. <i>Organic Letters</i> , 2017, 19, 4572-4575.	2.4	64

#	ARTICLE	IF	CITATIONS
19	(<i>R</i>)-Ketamine exerts antidepressant actions partly via conversion to (<i>2R,6R</i>)-hydroxynorketamine, while causing adverse effects at subanaesthetic doses. <i>British Journal of Pharmacology</i> , 2019, 176, 2573-2592.	2.7	61
20	Optical properties of photochromic fluorinated indolylfulgides. <i>Journal of Photochemistry and Photobiology A: Chemistry</i> , 2001, 144, 83-91.	2.0	60
21	Overcoming adaptive therapy resistance in AML by targeting immune response pathways. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	54
22	Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications. <i>Pharmacological Reviews</i> , 2021, 73, 763-791.	7.1	54
23	Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell Cultures. <i>Journal of Infectious Diseases</i> , 2018, 218, S672-S678.	1.9	49
24	Tuning the Optical Properties of Fluorinated Indolylfulgimides. <i>Journal of Organic Chemistry</i> , 2003, 68, 319-326.	1.7	46
25	Improved Synthesis of Indolyl Fulgides. <i>Journal of Organic Chemistry</i> , 2001, 66, 1914-1918.	1.7	41
26	Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (<i>2R,6R</i>)-hydroxynorketamine. <i>Journal of Psychopharmacology</i> , 2019, 33, 12-24.	2.0	41
27	Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 1624-1629.	3.3	38
28	Overcoming Acquired Epigenetic Resistance to BTK Inhibitors. <i>Blood Cancer Discovery</i> , 2021, 2, 630-647.	2.6	30
29	Zanos et al. reply. <i>Nature</i> , 2017, 546, E4-E5.	13.7	29
30	Optical and thermal properties of photochromic fluorinated adamantylidene indolylfulgides. <i>Journal of Photochemistry and Photobiology A: Chemistry</i> , 2002, 147, 39-44.	2.0	25
31	Targeting AML-associated FLT3 mutations with a type I kinase inhibitor. <i>Journal of Clinical Investigation</i> , 2020, 130, 2017-2023.	3.9	23
32	Pharmacological and genomic profiling of neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells. <i>Scientific Data</i> , 2018, 5, 180106.	2.4	20
33	Thermolysis of a Fluorinated Indolylfulgide Features a Novel 1,5-Indolyl Shift. <i>Journal of Organic Chemistry</i> , 2001, 66, 4739-4741.	1.7	19
34	Hydroxynorketamine Pharmacokinetics and Antidepressant Behavioral Effects of (<i>2R,6R</i>)- and (<i>5R,6R</i>)-Methyl-(<i>2R,6R</i>)-hydroxynorketamines. <i>ACS Chemical Neuroscience</i> , 2022, 13, 510-523.	1.7	15
35	Structure-activity relationship studies and biological characterization of human NAD ⁺ -dependent 15-hydroxyprostaglandin dehydrogenase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 630-635.	1.0	13
36	Targeting the PI3K/mTOR Pathway Augments CHK1 Inhibitor-Induced Replication Stress and Antitumor Activity in High-Grade Serous Ovarian Cancer. <i>Cancer Research</i> , 2020, 80, 5380-5392.	0.4	13

#	ARTICLE	IF	CITATIONS
37	Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs against Ebola Virus In Vivo. <i>Microorganisms</i> , 2021, 9, 566.	1.6	13
38	The Remarkable Selectivity of Nirmatrelvir. <i>ACS Pharmacology and Translational Science</i> , 2022, 5, 445-447.	2.5	13
39	KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. <i>Neuro-Oncology Advances</i> , 2020, 2, i62-i74.	0.4	12
40	Rigosertib Induces Mitotic Arrest and Apoptosis in RAS-Mutated Rhabdomyosarcoma and Neuroblastoma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 307-319.	1.9	12
41	Rilpivirine analogs potently inhibit drug-resistant HIV-1 mutants. <i>Retrovirology</i> , 2016, 13, 11.	0.9	10
42	Pyruvate Kinase M1 Suppresses Development and Progression of Prostate Adenocarcinoma. <i>Cancer Research</i> , 2022, 82, 2403-2416.	0.4	10
43	Cancer network activity associated with therapeutic response and synergism. <i>Genome Medicine</i> , 2016, 8, 88.	3.6	7
44	Novel renal medullary carcinoma cell lines, <scp>UOK353</scp> and <scp>UOK360</scp>, provide preclinical tools to identify new therapeutic treatments. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 472-483.	1.5	7
45	Apilimod. <i>IUCrData</i> , 2017, 2, .	0.1	4
46	A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1246-1258.	1.9	2